Agenus lowers warrant exercise price to $7.50; Ligand releases liens on assets

AGENUS INC

Modified warrant exercise price from $17.30 to $7.50 per share as part of Amendment Agreement with Ligand.
Ligand released liens on certain of Agenus' assets in exchange for the reduced warrant price.
Agreement executed Jan 3, 2026; full terms will be filed in upcoming 10-K.
The modification is dilutive to existing shareholders if warrant is exercised.

item 1.01 item 3.03

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AGENUS INC amended Amendment Agreement with Ligand Pharmaceuticals Incorporated (effective 2026-01-03).

Action: amendment
Agreement: asset purchase
Counterparty: Ligand Pharmaceuticals Incorporated
Effective: 2026-01-03

Exact text from the filing

On January 3, 2026, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into an amendment and release agreement (the “Amendment Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) related to a Purchase and Sale Agreement and related Warrant each previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on May 7, 2024.

View on SEC.gov

295 material agreements filed in the last 30 days. Browse all material agreements →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-007706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.